Literature DB >> 33561939

Targeting Beclin1 as an Adjunctive Therapy against HIV Using Mannosylated Polyethylenimine Nanoparticles.

Myosotys Rodriguez1, Yemmy Soler1, Mohan Kumar Muthu Karuppan1, Yuling Zhao2, Elena V Batrakova2, Nazira El-Hage1.   

Abstract

Using nanoparticle-based RNA interference (RNAi), we have previously shown that silencing the host autophagic protein, Beclin1, in HIV-infected human microglia and astrocytes restricts HIV replication and its viral-associated inflammatory responses. Here, we confirmed the efficacy of Beclin1 small interfering RNA (siBeclin1) as an adjunctive antiviral and anti-inflammatory therapy in myeloid human microglia and primary human astrocytes infected with HIV, both with and without exposure to combined antiretroviral (cART) drugs. To specifically target human microglia and human astrocytes, we used a nanoparticle (NP) comprised of linear cationic polyethylenimine (PEI) conjugated with mannose (Man) and encapsulated with siBeclin1. The target specificity of the PEI-Man NP was confirmed in vitro using human neuronal and glial cells transfected with the NP encapsulated with fluorescein isothiocyanate (FITC). PEI-Man-siBeclin1 NPs were intranasally delivered to healthy C57BL/6 mice in order to report the biodistribution of siBeclin1 in different areas of the brain, measured using stem-loop RT-PCR. Postmortem brains recovered at 1-48 h post-treatment with the PEI-Man-siRNA NP showed no significant changes in the secretion of the chemokines regulated on activation, normal T cell expressed and secreted (RANTES) and monocyte chemotactic protein-1 (MCP-1) and showed significant decreases in the secretion of the cytokines interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α) when compared to phosphate-buffered saline (PBS)-treated brains. Nissl staining showed minimal differences between the neuronal structures when compared to PBS-treated brains, which correlated with no adverse behavioral affects. To confirm the brain and peripheral organ distribution of PEI-siBeclin1 in living mice, we used the In vivo Imaging System (IVIS) and demonstrated a significant brain accumulation of siBeclin1 through intranasal administration.

Entities:  

Keywords:  Beclin1; HIV; in vivo imaging system; intranasal delivery; polyethylenimine nanoparticle

Year:  2021        PMID: 33561939      PMCID: PMC7915950          DOI: 10.3390/pharmaceutics13020223

Source DB:  PubMed          Journal:  Pharmaceutics        ISSN: 1999-4923            Impact factor:   6.321


  75 in total

1.  Identification and functional characterization of the mannose receptor in astrocytes.

Authors:  E M Burudi; S Riese; P D Stahl; A Régnier-Vigouroux
Journal:  Glia       Date:  1999-01       Impact factor: 7.452

2.  Intranasal administration as a route for drug delivery to the brain: evidence for a unique pathway for albumin.

Authors:  Joseph A Falcone; Therese S Salameh; Xiang Yi; Benjamin J Cordy; William G Mortell; Alexander V Kabanov; William A Banks
Journal:  J Pharmacol Exp Ther       Date:  2014-07-15       Impact factor: 4.030

3.  Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.

Authors:  Suzanne Craft; Laura D Baker; Thomas J Montine; Satoshi Minoshima; G Stennis Watson; Amy Claxton; Matthew Arbuckle; Maureen Callaghan; Elaine Tsai; Stephen R Plymate; Pattie S Green; James Leverenz; Donna Cross; Brooke Gerton
Journal:  Arch Neurol       Date:  2011-09-12

4.  Cerebrospinal fluid concentrations of tenofovir and emtricitabine in the setting of HIV-1 protease inhibitor-based regimens.

Authors:  Cecile D Lahiri; Kedria Reed-Walker; Anandi N Sheth; Edward P Acosta; Aswani Vunnava; Ighovwerha Ofotokun
Journal:  J Clin Pharmacol       Date:  2015-10-20       Impact factor: 3.126

Review 5.  Compartment-specific dynamics and functions of autophagy in neurons.

Authors:  Vineet Vinay Kulkarni; Sandra Maday
Journal:  Dev Neurobiol       Date:  2017-12-15       Impact factor: 3.964

6.  Differential role of autophagy in CD4 T cells and macrophages during X4 and R5 HIV-1 infection.

Authors:  Lucile Espert; Mihayl Varbanov; Véronique Robert-Hebmann; Sophie Sagnier; Ian Robbins; Françoise Sanchez; Virginie Lafont; Martine Biard-Piechaczyk
Journal:  PLoS One       Date:  2009-06-03       Impact factor: 3.240

Review 7.  The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research.

Authors:  Lavanya Varatharajan; Sarah A Thomas
Journal:  Antiviral Res       Date:  2009-01-25       Impact factor: 5.970

8.  Intranasal administration of elastin-like polypeptide for therapeutic delivery to the central nervous system.

Authors:  Jeremy Wd McGowan; Qingmei Shao; Parminder Js Vig; Gene L Bidwell
Journal:  Drug Des Devel Ther       Date:  2016-09-06       Impact factor: 4.162

Review 9.  Targeting with nanoparticles for the therapeutic treatment of brain diseases.

Authors:  Guang-Zhen Jin; Atanu Chakraborty; Jung-Hwan Lee; Jonathan C Knowles; Hae-Won Kim
Journal:  J Tissue Eng       Date:  2020-03-04       Impact factor: 7.813

View more
  1 in total

Review 1.  DAMPs and RAGE Pathophysiology at the Acute Phase of Brain Injury: An Overview.

Authors:  Baptiste Balança; Laurent Desmurs; Jérémy Grelier; Armand Perret-Liaudet; Anne-Claire Lukaszewicz
Journal:  Int J Mol Sci       Date:  2021-02-28       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.